Sickle Cell Disease Treatment Market Economic Outlook, Structure Analysis forecast by 2026


Posted July 19, 2021 by KunjalSharma

Global Sickle Cell Disease Treatment Market By Type (Hemoglobin Sβ0 Thalassemia, Hemoglobin Sβ+ Thalassemia, Hemoglobin SC, Others), Symptoms Type (Anemia, Episodes of Pain, Frequent Infections, Others),

 
Market Analysis: Global Sickle Cell Disease Treatment Market
Sickle cell disease treatment market is rising gradually with a healthy CAGR of 11.5% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Increasing incidence of sickle cell disease in different regions and high demand of unmet medical needs are driving the global sickle cell disease treatment market.
Market Definition: Global Sickle Cell Disease Treatment Market
Sickle cell disease (SCD) is the most common hereditary blood disorders. In this condition, red blood cells fail to supply adequate amount of oxygen in body. Normally red blood cells are flexible and round but in SDC obtain irregular shapes such as sickle or crescent moons and get stuck in small blood vessels blocking the way of blood flow.
The presence of SCD in black Americans is approximately 8%. The expected prevalence of sickle cell anemia in the United States is 1 in 625 persons at birth.
Get More Insights About Global Sickle Cell Disease Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sickle-cell-disease-treatment-market
Market Drivers
• Increase in immigration of African population can be the major driver for growth of the market
• Improvement in healthcare services and investment in treatment of sickle cell disease propel the market growth
• Rising cases of sickle cell diseases in North America region can boost up the global market growth
• High demand of regenerative therapies and strong pipeline may escalate the market in the forecast period
Market Restraints
• Lack of effective treatment options in Middle-East and Africa plays important role in challenging the market growth
• Unavailability of drugs in rural areas is obstructing the growth of the market
• High cost of treatment and low healthcare expenditure in some countries may hamper the market growth
Segmentation: Global Sickle Cell Disease Treatment Market
By Type
• Hemoglobin Sβ0 Thalassemia
• Hemoglobin Sβ+ Thalassemia
• Hemoglobin SC
• Others
By Symptoms
• Anemia
• Episodes of Pain
• Frequent Infections
• Others
By Complications
• Stroke
• Acute Chest Syndrome
• Pulmonary Hypertension
• Organ Damage
• Others
By Treatment
• Medication
• Blood Transfusion
• Bone Marrow Transplantation
• Others
By Medications
• Antibiotics
• Pain-Relieving Medications
• Hydroxyurea
• Others
By Route of Administration
• Oral
• Injectable
• Others
By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Distribution Channels
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• South America
o Brazil
o Rest of South America
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Turkey
o Belgium
o Netherlands
o Switzerland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o South Korea
o India
o Australia
o Singapore
o Thailand
o Malaysia
o Indonesia
o Philippines
o Rest of Asia-Pacific
• Middle East & Africa
o South Africa
o Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-sickle-cell-disease-treatment-market
Key Developments in the Market:
• In July 2019, Novartis AG received the Biologics License Application (BLA) for crizanlizumab (SEG101), an investigational sickle cell medicine used for preventing vaso-occlusive crises (VOCs) in patients with sickle cell disease. This BLA grant to the drug candidate of Novartis AG will provide the marketing authorizations of the drug in interstate market and supports the development of the product for commercialization internationally
• In December 2017, Addmedica received the U.S. FDA approval for Siklos (hydroxyurea), a drug that reduces the frequency of painful crises and blood transfucion requirements in pediatric patients suffering from sicle cell anemia. The approval is a major development for treatment of children with sickle cell anemia
Competitive Analysis:
Global sickle cell disease treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of sickle cell disease treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get Access Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-sickle-cell-disease-treatment-market
Key Market Players:
Few of the major competitors currently working in global sickle cell disease treatment market are Addmedica, Emmaus Medical, Inc., Global Blood Therapeutics Inc., bluebird bio, Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Limited, CELGENE CORPORATION, Ironwood Pharmaceuticals, Inc., Amgen Inc., Zydus Cadila, Silver Lake Research Corporation, Ionis Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Alkem Labs, Purdue Pharma L.P among others.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-sickle-cell-disease-treatment-market
Browse Trending Related Reports @
• Primary Sclerosing Cholangitis Market
• Pemphigoid Drug Market
• Uterine Cancer Drug Market
• Pharmacy Automation Market
• Persistent corneal epithelial defects treatment market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By DBMR
Country United States
Categories Business
Last Updated July 19, 2021